{"title":"二极管阴道激光联合盆底椅治疗绝经期泌尿生殖系统综合征。","authors":"Minie Anand, Winie Gautam, Manjusha Mohan, Nikhil Anand, Sinha Manjari","doi":"10.6026/973206300211606","DOIUrl":null,"url":null,"abstract":"<p><p>Genitourinary syndrome of menopause (GSM) is a common condition in postmenopausal women, marked by vaginal atrophy, dyspareunia, urinary incontinence and reduced sexual function. This study evaluated 50 women aged 45-70 years receiving 1470 nm diode laser therapy monthly for three months and pelvic floor chair therapy twice weekly for six weeks. Significant improvements were observed, with VAS scores for vaginal dryness and dyspareunia decreasing markedly, FSFI scores improving and urinary incontinence symptoms reducing as reflected by lower ICIQ-UI SF scores (all p < 0.001). The combined treatment demonstrated substantial symptomatic relief and enhancement of quality of life. Thus, a safe and effective non-hormonal approach for managing GSM is suggested.</p>","PeriodicalId":8962,"journal":{"name":"Bioinformation","volume":"21 6","pages":"1606-1611"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449489/pdf/","citationCount":"0","resultStr":"{\"title\":\"Management of genitourinary syndrome of menopause using diode vaginal laser combined with pelvic floor chair.\",\"authors\":\"Minie Anand, Winie Gautam, Manjusha Mohan, Nikhil Anand, Sinha Manjari\",\"doi\":\"10.6026/973206300211606\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Genitourinary syndrome of menopause (GSM) is a common condition in postmenopausal women, marked by vaginal atrophy, dyspareunia, urinary incontinence and reduced sexual function. This study evaluated 50 women aged 45-70 years receiving 1470 nm diode laser therapy monthly for three months and pelvic floor chair therapy twice weekly for six weeks. Significant improvements were observed, with VAS scores for vaginal dryness and dyspareunia decreasing markedly, FSFI scores improving and urinary incontinence symptoms reducing as reflected by lower ICIQ-UI SF scores (all p < 0.001). The combined treatment demonstrated substantial symptomatic relief and enhancement of quality of life. Thus, a safe and effective non-hormonal approach for managing GSM is suggested.</p>\",\"PeriodicalId\":8962,\"journal\":{\"name\":\"Bioinformation\",\"volume\":\"21 6\",\"pages\":\"1606-1611\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449489/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioinformation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6026/973206300211606\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioinformation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6026/973206300211606","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Management of genitourinary syndrome of menopause using diode vaginal laser combined with pelvic floor chair.
Genitourinary syndrome of menopause (GSM) is a common condition in postmenopausal women, marked by vaginal atrophy, dyspareunia, urinary incontinence and reduced sexual function. This study evaluated 50 women aged 45-70 years receiving 1470 nm diode laser therapy monthly for three months and pelvic floor chair therapy twice weekly for six weeks. Significant improvements were observed, with VAS scores for vaginal dryness and dyspareunia decreasing markedly, FSFI scores improving and urinary incontinence symptoms reducing as reflected by lower ICIQ-UI SF scores (all p < 0.001). The combined treatment demonstrated substantial symptomatic relief and enhancement of quality of life. Thus, a safe and effective non-hormonal approach for managing GSM is suggested.